Feil Family Brain & Mind Research Institute

Publications

Found 18 results
Author [ Title(Desc)] Type Year
Filters: Author is Vartanian, Timothy  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Telesford KM, Kaunzner UW, Perumal J, Gauthier SA, Wu X, Díaz I, Kruse-Hoyer M, Engel C, Marcille M, Vartanian T.  2020.  Black African and Latino/a identity correlates with increased plasmablasts in MS.. Neurol Neuroimmunol Neuroinflamm. 7(1)
C
Shetty SV, Mazzucco MR, Winokur P, Haigh SV, Rumah KRashid, Fischetti VA, Vartanian T, Linden JR.  2023.  Clostridium perfringens Epsilon Toxin Binds to and Kills Primary Human Lymphocytes.. Toxins (Basel). 15(7)
Linden JR, Ma Y, Zhao B, Harris JMichael, Rumah KRashid, Schaeren-Wiemers N, Vartanian T.  2015.  Clostridium perfringens Epsilon Toxin Causes Selective Death of Mature Oligodendrocytes and Central Nervous System Demyelination.. MBio. 6(3):e02513.
Linden JR, Flores C, Schmidt EF, Uzal FA, Michel AO, Valenzuela M, Dobrow S, Vartanian T.  2019.  Clostridium perfringens epsilon toxin induces blood brain barrier permeability via caveolae-dependent transcytosis and requires expression of MAL.. PLoS Pathog. 15(11):e1008014.
D
Williams MJ, Okai AF, Cross AH, Monson NL, Vartanian T, Thrower BW, Reder AT, English JB, Wu GF, Bernitsas E et al..  2023.  Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial.. Mult Scler Relat Disord. 76:104794.
Al-Kawaz M, Monohan E, Morris E, Perumal JS, Nealon N, Vartanian T, Gauthier SA.  2017.  Differential Impact of Multiple Sclerosis on Cortical and Deep Gray Matter Structures in African Americans and Caucasian Americans.. J Neuroimaging. 27(3):333-338.
E
Ma Y, Sannino D, Linden JR, Haigh S, Zhao B, Grigg JB, Zumbo P, Dündar F, Butler DJ, Profaci CP et al..  2023.  Epsilon toxin-producing Clostridium perfringens colonize the MS gut and epsilon toxin overcomes immune privilege.. J Clin Invest.
I
Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS.  2018.  Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.. Mult Scler. 24(4):540-542.
Pandya S, Kaunzner UW, Rúa SMHurtado, Nealon N, Perumal J, Vartanian T, Nguyen TD, Gauthier SA.  2020.  Impact of Lesion Location on Longitudinal Myelin Water Fraction Change in Chronic Multiple Sclerosis Lesions.. J Neuroimaging. 30(4):537-543.
Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS.  2018.  Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.. J Neurol. 265(5):1226-1229.
M
Vargas WS, Monohan E, Pandya S, Raj A, Vartanian T, Nguyen TD, Rúa SMHurtado, Gauthier SA.  2015.  Measuring longitudinal myelin water fraction in new multiple sclerosis lesions.. Neuroimage Clin. 9:369-75.
Rumah KRashid, Ma Y, Linden JR, Oo MLin, Anrather J, Schaeren-Wiemers N, Alonso MA, Fischetti VA, McClain MS, Vartanian T.  2015.  The Myelin and Lymphocyte Protein MAL Is Required for Binding and Activity of Clostridium perfringens ε-Toxin.. PLoS Pathog. 11(5):e1004896.
N
Telesford KM, Smith C, Mettlen M, Davis MB, Cowell L, Kittles R, Vartanian T, Monson N.  2023.  Neuron-binding antibody responses are associated with Black ethnicity in multiple sclerosis during natalizumab treatment.. Brain Commun. 5(4):fcad218.
R
Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, Vartanian T, Kuceyeski A, Vallabhajosula S, P Mozley D et al..  2017.  Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.. Mult Scler Relat Disord. 15:27-33.
Bennett JL, Nickerson M, Costello F, Sergott RC, Calkwood JC, Galetta SL, Balcer LJ, Markowitz CE, Vartanian T, Morrow M et al..  2015.  Re-evaluating the treatment of acute optic neuritis.. J Neurol Neurosurg Psychiatry. 86(7):799-808.
Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D et al..  2016.  Relapses in multiple sclerosis: Relationship to disability.. Mult Scler Relat Disord. 6:10-20.
S
Kaunzner UW, Kumar G, Askin G, Gauthier SA, Nealon NN, Vartanian T, Perumal JS.  2016.  A study of patients with aggressive multiple sclerosis at disease onset.. Neuropsychiatr Dis Treat. 12:1907-12.
T
Ranganathan U, Kaunzner U, Foster S, Vartanian T, Perumal JS.  2018.  Thrombocytopenia at the time of alemtuzumab infusion in relapsing-remitting multiple sclerosis.. Mult Scler. 24(4):553-554.